New inhaled asthma drug begins first human safety trial
NCT ID NCT07665892
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a single inhaled dose of ASY202, a drug containing dihydroergotamine, in 40 adults with stable asthma. The study is randomized and placebo-controlled, meaning some participants get the drug and some get an inactive powder. The main goal is to check safety and how the drug moves through the body, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASY202 (dihydroergotamine dry powder for inhalation)
What this could lead to
If safe and effective, this could point toward a new inhaled treatment to ease asthma symptoms.
What could go wrong
This is a very early Phase 1 safety trial with only 40 people, so it may not show clear benefit or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY IN ASTHMA PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun City Clinical Research
RECRUITINGGlendale, Arizona, 85304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Worldwide Clinical Trials- Early Phase Research Unit
RECRUITINGSan Antonio, Texas, 78217, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact